Norwegian smart systems provider Thin Film Electronics (Thinfilm) has entered a collaboration with Swiss medical technology firm Ypsomed Group to develop new medical injection and infusion systems.

The systems will be designed to support the administration of medications with intelligent electronic and software-based additional functions.

Under the deal, Ypsomed intends to invest CHF50m ($51.2m) in the research and development of the injection and infusion systems.

The deal will see Thinfilm integrate its NFC OpenSense technology in YpsoMate autoinjectors to improve patient self-care compliance.

Ypsomed CEO Simon Michel said: "We believe Thinfilm’s NFC OpenSense can be of significant value to YpsoMate users across the globe, and we look forward to leveraging this next-generation technology to help improve patient adherence."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We believe Thinfilm’s NFC OpenSense can be of significant value to YpsoMate users across the globe."

YpsoMate autoinjectors are disposable two-step injection systems, which have pre-filled glass or polymer syringes, and will be operated by push-on-skin activation.

Autoinjectors are used by patients to self-deliver periodic injections for ongoing management of chronic conditions such as rheumatoid arthritis or cardiovascular indications.

Thinfilm CEO Davor Sutija said: "Ypsomed is at the forefront of self-medication delivery systems, and it’s clear that a focus on user-friendly products and the patient experience has played a key role in their success."

Patients can receive compliance assistance such as adherence history, injection reminders, usage guidelines, refill instructions and authentication through the combination of the NFC OpenSense tags and a custom mobile app.

NFC OpenSense tags are thin and flexible labels that will detect the state before and after injection of the YpsoMate Smart autoinjector.

The content will be wirelessly delivered to patients through a smartphone and records patients’ interactions with the YpsoMate Smart device in the cloud.

Image: Thinfilm’s NFC OpenSense on Ypsomed’s YpsoMate autoinjector. Photo: courtesy of Business Wire / Thin Film Electronics.